HOFFMANN-LA ROCHE

PASEDENA

This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients.

Status: ACTIVE, NOT RECRUITING

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.